Approval Criteria Department of Pharmacy Services

**Generic Name**: Hyaluronate acid derivatives

**Brand Name**: Euflexxa, Hylan, Supartz, Orthovisc, Synvisc, Synvisc-one, Gel-One

**Medication Class**: Viscosupplements

**FDA Approved Uses**
- Intra-articular injections for treatment of mild to moderate osteoarthritis of knees

**Criteria for use**
- Clinically documented osteoarthritis of knees
- Efficacy of intra-articular corticosteroid injection lasting less than 6 weeks
- Trial, failure, or intolerance to at least two (2) NSAID’s

**Not Approved For**
- Request is to inject into joints other than knees
- Member has any evidence of allergy to avian or avian-derived products, including eggs (except for Euflexxa)
- Any contraindication to use of the product

**Required Medical Information**
- Clinical documentation of diagnosis
- Clinical documentation of dates of intra-articular corticosteroid injections and response to treatment
- Clinical documentation or claims history of previous treatment with NSAIDs and response to therapy

**Contraindications**
- Hypersensitivity to hyaluronan or any components of the product
- Know allergies to avian or avian-derived products, including eggs, feathers, or poultry (except Euflexxa)
- Infections or skin diseases in the area of the injection site or joint

**Dosing**
- **Euflexxa**
  - Inject 20 mg (2ml) into affected knee at weekly intervals for 3 weeks, for a total of 3 injections
- **Hylan**
  - Inject 20mg (2ml) once weekly for a total of 5 injections
- **Orthovisc**
  - Inject 30mg (2ml) 1 week apart for 3 – 4 injections
- **Supartz**
  - Inject 25 mg (2.5ml) once weekly for total of 3 injections
- **Synvisc**
  - Inject 16 mg (2ml) once weekly for a total of 3 injections
- **Synvisc-One**:
  - Inject 48 mg (6ml) one time only
Authorization

- Euflexxa: QL = 3 over 3 weeks
- Hyalgan: QL = 5 over 5 weeks
- Orthovisc: QL = 4 over 4 weeks
- Supartz: QL = 5 over 5 weeks
- Synvisc: QL = 3 over 3 weeks
- Synvisc-One: QL = 1

Repeated courses of therapy are not indicated with Euflexxa or Supartz
Repeated courses of therapy with Hyalgan, Orthovisc, or Synvisc have not been studied for safety

Approved by P&T Committee: 5/14/2013

References